Effect of intercalated erlotinib with gemcitabine/cisplatin as neoadjuvant treatment in stage IIIA unrectable non-small cell lung cancer (CTONG 1101, NCT01297101) on disease-free survival: A single arm, multi-center, phase II study.

被引：0
|
作者：
Chen Zhiwei
Jiang Gening
Xin, Wang
Luo, Qingquan
Lu, Shun
机构：
[1] Jiao Tong Univ, Shanghai Chest Hosp, Dept Shanghai Lung Canc Ctr, Shanghai 200030, Peoples R China
[2] Tongji Univ, Sch Med, Shanghai Pulm Hosp, Dept Surg Oncol, Shanghai 200092, Peoples R China
[3] Sun Yat Sen Univ, Ctr Canc, Dept Surg Oncol, Shanghai, Peoples R China
[4] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
[5] Shanghai Chest Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18519
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A SINGLE ARM, MULTI-CENTER, PHASE II STUDY OF INTERCALATED ERLOTINIB WITH GEMCITABINE/CISPLATIN AS NEOADJUVANT TREATMENT IN STAGE IIIA NON-SMALL CELL LUNG CANCER (CTONG 1101, NCT01297101): PRELIMINARY RESULT
    Lu, Shun
    Jiang, Gening
    Chen, Zhiwei
    Wang, Xin
    Luo, Qingquan
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S556 - S557
  • [2] Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 EGFR-Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study
    Zhong, Wen-Zhao
    Chen, Ke-Neng
    Chen, Chun
    Gu, Chun-Dong
    Wang, Jun
    Yang, Xue-Ning
    Mao, Wei-Min
    Wang, Qun
    Qiao, Gui-Bin
    Cheng, Ying
    Xu, Lin
    Wang, Chang-Li
    Chen, Ming-Wei
    Kang, Xiaozheng
    Yan, Wanpu
    Yan, Hong-Hong
    Liao, Ri-Qiang
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Zhou, Qing
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (25) : 2235 - +
  • [3] Neoadjuvant Camrelizumab Combined with Chemotherapy for Resectable Stage IIIA-IIIB Non-Small Cell Lung Cancer: Single Arm Phase II Study
    Cai, G.
    Wang, K.
    Wang, X.
    Zhao, J.
    Wang, Z.
    Han, X.
    Zhou, H.
    Xie, C.
    Fu, S.
    Hui, J.
    Huang, Y.
    Li, W.
    Teng, F.
    Wang, S.
    Yu, J.
    Song, P.
    Meng, X.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E10 - E10
  • [4] Neoadjuvant camrelizumab combined with chemotherapy for resectable stage IIIA-IIIb non-small cell lung cancer: Single arm phase II study
    Cai, Guoxin
    Wang, Kaiyue
    Wang, Xiaohan
    Zhao, Jiarui
    Han, Xiao
    Zhou, Haiyan
    Xie, Chao
    Jia, Hui
    Fu, Shuai
    Huang, Yong
    Li, Wanhu
    Teng, Feifei
    Wang, Suzhen
    Yu, Jinming
    Song, Pingping
    Meng, Xue
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer.
    Wu, Yi-Long
    Zhong, Wenzhao
    Chen, Ke-Neng
    Chen, Chun
    Yang, Fan
    Yang, Xue-Ning
    Gu, Chundong
    Mao, Weimin
    Wang, Qun
    Qiao, Gui-Bin
    Cheng, Ying
    Xu, Lin
    Wang, Changli
    Chen, Mingwei
    Yan, Hong-Hong
    Liao, Ri-qiang
    Zhang, Xuchao
    Yang, Jinji
    Liu, Si-yang
    Zhou, Qing
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Paclitaxel, cisplatin and gemcitabine combination chemotherapy in stage IV non-small cell lung cancer (NSCLC):: A phase II study.
    Cortes, J
    Rodriguez, J
    Calvo, E
    Martinez-Monge, R
    Fernández-Hildago, O
    Garzón, C
    Santisteban, M
    de Irala, J
    Azinovic, I
    Brugarolas, A
    ANNALS OF ONCOLOGY, 2000, 11 : 118 - 118
  • [7] Intercalated combination of chemotherapy and erlotinib for stage IIIA non-small-cell lung cancer: a multicenter, open-label, single-arm, phase II study
    Chen, Zhiwei
    Shen, Shengping
    Shi, Wenbo
    Jiang, Gening
    Wang, Xin
    Jian, Hong
    Zhou, Zhen
    Ding, Zhengping
    Lu, Shun
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 6543 - 6552
  • [8] Cisplatin and gemcitabine (GC) as neoadjuvant therapy of stage III unresectable non-small cell lung cancer (NSCLC):: A phase II study
    Mazzoni, F
    Di Stefano, A
    Maestri, A
    Calandri, C
    Mosconi, AM
    De Marinis, F
    Scagliotti, GV
    Selvaggi, G
    Crinò, L
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 8 - 8
  • [9] Erlotinib as Neoadjuvant Therapy in Stage IIIA (N2) EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Prospective, Single-Arm, Phase II Study
    Xiong, Liwen
    Li, Rong
    Sun, Jiayuan
    Lou, Yuqing
    Zhang, Weiyan
    Bai, Hao
    Wang, Huiming
    Shen, Jie
    Jing, Bo
    Shi, Chunlei
    Zhong, Hua
    Gu, Aiqin
    Jiang, Liyan
    Shi, Jianxing
    Fang, Wentao
    Zhao, Heng
    Zhang, Jie
    Wang, Junyuan
    Ye, Junyi
    Han, Baohui
    ONCOLOGIST, 2019, 24 (02): : 157 - +
  • [10] Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial
    Zhong, Wen-Zhao
    Yan, Hong-Hong
    Chen, Ke-Neng
    Chen, Chun
    Gu, Chun-Dong
    Wang, Jun
    Yang, Xue-Ning
    Mao, Wei-Min
    Wang, Qun
    Qiao, Gui-Bin
    Cheng, Ying
    Xu, Lin
    Wang, Chang-Li
    Chen, Ming-Wei
    Kang, Xiao-Zheng
    Yan, Wan-Pu
    Liao, Ri-Qiang
    Yang, Jin-Ji
    Zhang, Xu-Chao
    Liu, Si-Yang
    Zhou, Qing
    Wu, Yi-Long
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
12345